Moreover, the 36-month beta value for RCKT is 1.01. Analysts have varying opinions on the stock, with 12 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for RCKT is 96.86M and currently, short sellers hold a 11.54% of that float. On December 26, 2024, RCKT’s average trading volume was 1.08M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
RCKT) stock’s latest price update
The stock of Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has increased by 2.19 when compared to last closing price of 11.43. Despite this, the company has experienced a 2.85% gain in its stock price over the last five trading sessions. investopedia.com reported 2024-12-18 that Shares of Rocket Pharmaceuticals (RCKT) jumped 5.5% intraday Wednesday as Jefferies initiated coverage of the biotech company with a “buy” rating on optimism about the experimental drugs in its pipeline. Jefferies also set a price target of $29, more than double its current value.
RCKT’s Market Performance
RCKT’s stock has risen by 2.85% in the past week, with a monthly drop of -13.11% and a quarterly drop of -33.59%. The volatility ratio for the week is 5.65% while the volatility levels for the last 30 days are 5.86% for Rocket Pharmaceuticals Inc The simple moving average for the last 20 days is -9.71% for RCKT stock, with a simple moving average of -41.99% for the last 200 days.
Analysts’ Opinion of RCKT
Many brokerage firms have already submitted their reports for RCKT stocks, with Jefferies repeating the rating for RCKT by listing it as a “Buy.” The predicted price for RCKT in the upcoming period, according to Jefferies is $29 based on the research report published on December 18, 2024 of the current year 2024.
Goldman gave a rating of “Neutral” to RCKT, setting the target price at $39 in the report published on April 02nd of the current year.
RCKT Trading at -21.91% from the 50-Day Moving Average
After a stumble in the market that brought RCKT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.09% of loss for the given period.
Volatility was left at 5.86%, however, over the last 30 days, the volatility rate increased by 5.65%, as shares sank -17.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.89% lower at present.
During the last 5 trading sessions, RCKT fell by -2.01%, which changed the moving average for the period of 200-days by -57.68% in comparison to the 20-day moving average, which settled at $12.91. In addition, Rocket Pharmaceuticals Inc saw -59.09% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RCKT starting from Militello John, who sale 1,224 shares at the price of $13.05 back on Nov 21 ’24. After this action, Militello John now owns 49,310 shares of Rocket Pharmaceuticals Inc, valued at $15,978 using the latest closing price.
Patel Kinnari, the of Rocket Pharmaceuticals Inc, sale 4,588 shares at $13.05 during a trade that took place back on Nov 21 ’24, which means that Patel Kinnari is holding 392,395 shares at $59,892 based on the most recent closing price.
Stock Fundamentals for RCKT
Current profitability levels for the company are sitting at:
- -26.55 for the present operating margin
- 0.05 for the gross margin
The net margin for Rocket Pharmaceuticals Inc stands at -25.03. The total capital return value is set at -0.77. Equity return is now at value -59.27, with -52.01 for asset returns.
Currently, EBITDA for the company is -236.62 million with net debt to EBITDA at 0.16. When we switch over and look at the enterprise to sales, we see a ratio of 116.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.05.
Conclusion
To wrap up, the performance of Rocket Pharmaceuticals Inc (RCKT) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
